DAVID LICKRISH
Highland Therapeutics
David Lickrish is the Founder, CEO and Chairman of Highland Therapeutics Inc. and Chief Executive Officer of Ironshore Pharmaceuticals & Development, Inc., a subsidiary of Highland Therapeutics.
Prior to founding Highland Therapeutics, David worked in Finance as a Senior Equity Research Analyst covering the Global Pharmaceutical Industry where he became familiar with Attention Deficit Hyperactivity Disorder (ADHD) and the unmet clinical needs associated with it such as early morning functioning (EMF). David recognized EMF as a significant challenge in the treatment of ADHD and used the knowledge garnered throughout his career to pursue potential solutions.
Transitioning from the world of finance to healthcare, David dedicated himself to the creation of a patented, oral, once-daily drug-delivery technology now known as DELEXIS®. This novel technology was designed to enable the administration of medicines in the evening with the objective of achieving a therapeutic effect early the next morning and lasting throughout the day.
Under his leadership, Ironshore has grown from a start-up research and development organization to an international pharmaceutical company with a proprietary drug-delivery technology and multiple late-stage drugs under development. Ironshore recently launched FDA-approved JORNAY PMTM indicated for the treatment of ADHD in patients 6 years and older in the United States. JORNAY PM is the first and only ADHD stimulant that is dosed in the evening and is working when patients wake up and lasts throughout the day and into the evening.
David studied Microbiology and Finance at the University of Guelph in Canada. He graduated with Honors and received his Bachelor of Commerce in International Economics and Finance. David has been a CFA Charter holder since 2001 and is the named inventor on more than 15 patents in the United States, Europe and Asia.
